|
US2020332348A1
|
|
Nucleic acid probes for in situ hybridization
|
|
US2019307842A1
|
|
Pharmaceutical compositions and methods targeting wnt pathway proteins
|
|
WO2020005313A1
|
|
Sphingosine pathway modulating compounds for the treatment of cancers
|
|
US2019111030A1
|
|
Sphingosine pathway modulating compounds for the treatment of cancers
|
|
US10364211B1
|
|
Methods and intermediates for synthesizing sk1-i
|
|
US10323272B1
|
|
Nucleic acid probes for in situ hybridization
|
|
US2018328943A1
|
|
Immunomodulatory compositions and methods of use thereof
|
|
WO2019018607A1
|
|
Immunomodulatory compositions and methods of use thereof
|
|
CA3061201A1
|
|
Sphingosine pathway modulating compounds for the treatment of cancers
|
|
US2018303932A1
|
|
Immunomodulatory pharmaceutical compositions and methods of use thereof
|
|
US2017232084A1
|
|
Immune modulation for the treatment of age-related macular degeneration
|
|
US2017204481A1
|
|
Comprehensive and comparative flow cytometry-based methods for identifying the state of a biological system
|
|
US2017198033A1
|
|
Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor
|
|
US2016289779A1
|
|
Monoazo dyes with cyclic amine as fluorescence quenchers
|
|
US2016177396A1
|
|
Comprehensive and comparative flow cytometry-based methods for identifying the state of a biological system
|
|
EP2943593A1
|
|
Diagnosis and treatment of herpesvirus saimiri associated diseases
|
|
US2015344976A1
|
|
Diagnosis and treatment of viral diseases
|
|
US2014193423A1
|
|
Diagnosis and treatment of viral diseases
|
|
US2014322188A1
|
|
Tolerizing treatments for autoimmune disease
|
|
US2014273021A1
|
|
Vitamin d assays
|
